Skip to content

Schema therapy for Anorexia Nervosa

Schema therapy for Anorexia Nervosa - Schema therapy for Anorexia Nervosa

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON53672
Enrollment
12
Registered
2023-02-23
Start date
2023-10-25
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eating disorder feeding disorder

Interventions

45 sessions schema therapy (in 50 weeks time)

Sponsors

Parnassia
Lead Sponsor

Eligibility

Age
16 Years to 64 Years

Inclusion criteria

Inclusion criteria: - A DSM-5 diagnosis anorexia nervosa - Age between 16-65 years - BMI >= 15 and somatically stabile as is defined in the department*s crisis protocol and evaluated by a physician specialised in eating disorders.

Exclusion criteria

Exclusion criteria: - Patients in an acute state of mental crisis who need immediate hospitalization or treatment for high suicide risk - Patients with intellectual disability - Patients who cannot complete the questionnaires because of insufficient language skills, practical or cognitive limitations - Not willing (or being able) to sign the informed consent form of this study

Design outcomes

Primary

MeasureTime frame
This study investigates the effects of a thirty week schema therapy in reducing eating disorder symptoms of patients with anorexia nervosa. Hypothesis: Based on previous research (McIntosh et al., 2016; Pauwels, Dierckx, Schoevaerts, & Claes, 2016; Pugh, 2015; Simpson et al., 2010; Waller, Dickson, & Ohanian, 2002) it is expected that schema therapy will improve eating disorder symptoms for patients with anorexia nervosa.

Secondary

MeasureTime frame
This study seeks to examine the changing nature of schema*s and modes in patients with anorexia nervosa during schema therapy. Hypothesis: It is expected to demonstrate a reduction in schema*s and modes for patients with anorexia nervosa during schema therapy.

Countries

Netherlands

Contacts

Public ContactI. Versteeg

Transparant

i.versteeg@psyq.nl0883572013

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)